<DOC>
	<DOC>NCT01364415</DOC>
	<brief_summary>This study designed to determine the Maximum Tolerated Dose (MTD) for patients with advanced Neuroendocrine Tumors (NETs) and to characterize the safety, tolerability, Pharmacokinetics and preliminary efficacy of pasireotide LAR administered i.m. once every 28 days.</brief_summary>
	<brief_title>Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<criteria>≥18 yrs old, histologically confirmed advanced well or moderately differentiated neuroendocrine tumor/carcinoma unresectable metastatic NET tumor with measurable disease life expectancy ≥ 12 weeks Patients with CNS metastases who are neurologically unstable or requiring increasing doses of steroids to control their CNS disease patients with known hypersensitivity to somatostatin analogs patients with symptomatic cholelithiasis in the past 2 months patients with history of another known primary malignancy with exception of nonmelanoma skin cancer or carcinoma in situ of uterine cervix patients with known history of hepatitis C or chronic active hepatitis B patients with diagnosis of HIV. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>MTD</keyword>
	<keyword>pasireotide</keyword>
	<keyword>LAR</keyword>
	<keyword>NETs</keyword>
	<keyword>advanced neuroendocrine tumors</keyword>
</DOC>